Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (S)-Bicalutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 9/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | GHSR | Q92847 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Bicalutamide SCHEMBL29354880 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL29353850 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL3611 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL3612 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1561110 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (S)-Bicalutamide SCHEMBL29444530 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL1933417 | 1.00 | AR (1.00) | ARCYP2C19ABCB11ALBPGR | |
| (R)-Bicalutamide SCHEMBL28262190 | 0.98 | AR (0.96) | ARCYP2C19ABCB11ALBPGR | |
| Bicalutamide SCHEMBL679554 | 0.97 | AR (0.94) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL15325704 | 0.93 | AR (0.87) | ARCYP2C19ABCB11ALBPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | BCN PEPTIDES, S.A. (ES) | 2023-02-07 | — | — | US | claimed |
| US-7199257-B1 | Process for the synthesis of N-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2007-04-03 | — | — | US | claimed |
| EP-1189898-B1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULPHONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | RICHTER GEDEON VEGYESZET (HU) | 2003-03-12 | — | — | EP | claimed |
| EP-1189898-A1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULPHONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2002-03-27 | — | — | EP | claimed |
| WO-2001000608-A1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULFONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2001-01-04 | — | — | WO | claimed |
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | BCN PEPTIDES, S.A. (ES) | 2023-02-07 | — | — | US | disclosed |
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | BCN PEPTIDES, S.A. (ES) | 2023-02-07 | — | — | US | disclosed |
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | BCN PEPTIDES, S.A. (ES) | 2023-02-07 | — | — | US | disclosed |
| CN-105828811-B | Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases | BCN肽类股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-105828811-B | Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases | BCN肽类股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| EP-3086784-B9 | BICALUTAMIDE ANALOGS OR (S)-BICALUTAMIDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN PEPTIDES SA (ES) | 2019-10-16 | — | — | EP | disclosed |
| EP-3086784-B1 | BICALUTAMIDE ANALOGS OR (S)-BICALUTAMIDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN PEPTIDES SA (ES) | 2019-03-27 | — | — | EP | disclosed |
| EP-1189898-B1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULPHONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | RICHTER GEDEON VEGYESZET (HU) | 2003-03-12 | — | — | EP | disclosed |
| EP-1189898-B1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULPHONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | RICHTER GEDEON VEGYESZET (HU) | 2003-03-12 | — | — | EP | disclosed |
| EP-1189898-A1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULPHONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2002-03-27 | — | — | EP | disclosed |
| EP-1189898-A1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULPHONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2002-03-27 | — | — | EP | disclosed |
| US-6291194-B1 | Assay for determination of androgenic or anti-androgenic activity of a serum sample or a test compound | HORMOS MEDICAL CORPORATION (FI) | 2001-09-18 | — | — | US | disclosed |
| WO-2001000608-A8 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULFONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | RICHTER GEDEON VEGYESZET (HU) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001000608-A1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULFONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2001-01-04 | — | — | WO | disclosed |
| WO-2001000608-A1 | PROCESS FOR THE SYNTHESIS OF N-(4-CYANO-3-TRIFLUOROMETHYLPHENYL)-3-(4-FLUOROPHENYLSULFONYL)-2-HYDROXY-2-METHYLPROPIONAMIDE | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | GBA1, GAA, GBA3 | AR 669/4885CYP2C19 4643/4885ABCB11 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.